Related Experiment Video
Updated: Apr 22, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Interventional treatment for unresectable hepatocellular carcinoma
Satoru Murata1, Takahiko Mine1, Fumie Sugihara1
1Satoru Murata, Takahiko Mine, Fumie Sugihara, Daisuke Yasui, Hidenori Yamaguchi, Tatsuo Ueda, Shiro Onozawa, Shin-ichiro Kumita, Department of Radiology/Center for Advanced Medical Technology, Nippon Medical School, Tokyo 113-8602, Japan.
Transcatheter arterial chemoembolization (TACE) and other interventional therapies offer improved outcomes for intermediate-stage hepatocellular carcinoma (HCC). Advanced-stage HCC requires more effective treatments beyond current standards like sorafenib.
Area of Science:
- Hepatobiliary Oncology
- Interventional Radiology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
- Current standard treatments for intermediate-stage HCC include transcatheter arterial chemoembolization (TACE).
- Advanced-stage HCC patients often receive suboptimal treatment with sorafenib or palliative care.
Purpose of the Study:
- To review current interventional treatments for unresectable HCC.
- To discuss technical advancements in interventional therapies.
- To highlight the need for improved treatments for advanced-stage HCC.
Main Methods:
- Review of published data on interventional treatments for HCC.
- Inclusion of data from ongoing clinical studies.
- Focus on technical improvements and evolving therapies.
Main Results:
- Interventional treatments like TACE, radioembolization, and combined therapies are evolving.
- These evolving treatments improve patient prognosis for intermediate-stage HCC.
- There is a critical need for more effective therapies for advanced-stage HCC beyond sorafenib.
Conclusions:
- Interventional radiology plays a crucial role in managing unresectable HCC.
- Ongoing research focuses on novel combined and modified interventional approaches.
- Further advancements are essential to improve outcomes for patients with advanced-stage HCC.
